Cargando…

PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo

Alveolar bone loss, the major feature of periodontitis, results from the activation of osteoclasts, which can consequently cause teeth to become loose and fall out; the development of drugs capable of suppressing excessive osteoclast differentiation and function is beneficial for periodontal disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Ihn, Hye-Jung, Kim, Yi-Seul, Lim, Soomin, Bae, Jong-Sup, Jung, Jae-Chang, Kim, Yeo-Hyang, Park, Jin-Woo, Wang, Zhao, Koh, Jeong-Tae, Bae, Yong-Chul, Baek, Moon-Chang, Park, Eui-Kyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919013/
https://www.ncbi.nlm.nih.gov/pubmed/33671948
http://dx.doi.org/10.3390/ijms22041915
_version_ 1783658052992368640
author Ihn, Hye-Jung
Kim, Yi-Seul
Lim, Soomin
Bae, Jong-Sup
Jung, Jae-Chang
Kim, Yeo-Hyang
Park, Jin-Woo
Wang, Zhao
Koh, Jeong-Tae
Bae, Yong-Chul
Baek, Moon-Chang
Park, Eui-Kyun
author_facet Ihn, Hye-Jung
Kim, Yi-Seul
Lim, Soomin
Bae, Jong-Sup
Jung, Jae-Chang
Kim, Yeo-Hyang
Park, Jin-Woo
Wang, Zhao
Koh, Jeong-Tae
Bae, Yong-Chul
Baek, Moon-Chang
Park, Eui-Kyun
author_sort Ihn, Hye-Jung
collection PubMed
description Alveolar bone loss, the major feature of periodontitis, results from the activation of osteoclasts, which can consequently cause teeth to become loose and fall out; the development of drugs capable of suppressing excessive osteoclast differentiation and function is beneficial for periodontal disease patients. Given the difficulties associated with drug discovery, drug repurposing is an efficient approach for identifying alternative uses of commercially available compounds. Here, we examined the effects of PF-3845, a selective fatty acid amide hydrolase (FAAH) inhibitor, on receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclastogenesis, its function, and the therapeutic potential for the treatment of alveolar bone destruction in experimental periodontitis. PF-3845 significantly suppressed osteoclast differentiation and decreased the induction of nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) and the expression of osteoclast-specific markers. Actin ring formation and osteoclastic bone resorption were also reduced by PF-3845, and the anti-osteoclastogenic and anti-resorptive activities were mediated by the suppression of phosphorylation of rapidly accelerated fibrosarcoma (RAF), mitogen-activated protein kinase (MEK), extracellular signal-regulated kinase, (ERK) and nuclear factor κB (NF-κB) inhibitor (IκBα). Furthermore, the administration of PF-3845 decreased the number of osteoclasts and the amount of alveolar bone destruction caused by ligature placement in experimental periodontitis in vivo. The present study provides evidence that PF-3845 is able to suppress osteoclastogenesis and prevent alveolar bone loss, and may give new insights into its role as a treatment for osteoclast-related diseases.
format Online
Article
Text
id pubmed-7919013
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79190132021-03-02 PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo Ihn, Hye-Jung Kim, Yi-Seul Lim, Soomin Bae, Jong-Sup Jung, Jae-Chang Kim, Yeo-Hyang Park, Jin-Woo Wang, Zhao Koh, Jeong-Tae Bae, Yong-Chul Baek, Moon-Chang Park, Eui-Kyun Int J Mol Sci Article Alveolar bone loss, the major feature of periodontitis, results from the activation of osteoclasts, which can consequently cause teeth to become loose and fall out; the development of drugs capable of suppressing excessive osteoclast differentiation and function is beneficial for periodontal disease patients. Given the difficulties associated with drug discovery, drug repurposing is an efficient approach for identifying alternative uses of commercially available compounds. Here, we examined the effects of PF-3845, a selective fatty acid amide hydrolase (FAAH) inhibitor, on receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclastogenesis, its function, and the therapeutic potential for the treatment of alveolar bone destruction in experimental periodontitis. PF-3845 significantly suppressed osteoclast differentiation and decreased the induction of nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) and the expression of osteoclast-specific markers. Actin ring formation and osteoclastic bone resorption were also reduced by PF-3845, and the anti-osteoclastogenic and anti-resorptive activities were mediated by the suppression of phosphorylation of rapidly accelerated fibrosarcoma (RAF), mitogen-activated protein kinase (MEK), extracellular signal-regulated kinase, (ERK) and nuclear factor κB (NF-κB) inhibitor (IκBα). Furthermore, the administration of PF-3845 decreased the number of osteoclasts and the amount of alveolar bone destruction caused by ligature placement in experimental periodontitis in vivo. The present study provides evidence that PF-3845 is able to suppress osteoclastogenesis and prevent alveolar bone loss, and may give new insights into its role as a treatment for osteoclast-related diseases. MDPI 2021-02-15 /pmc/articles/PMC7919013/ /pubmed/33671948 http://dx.doi.org/10.3390/ijms22041915 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ihn, Hye-Jung
Kim, Yi-Seul
Lim, Soomin
Bae, Jong-Sup
Jung, Jae-Chang
Kim, Yeo-Hyang
Park, Jin-Woo
Wang, Zhao
Koh, Jeong-Tae
Bae, Yong-Chul
Baek, Moon-Chang
Park, Eui-Kyun
PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo
title PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo
title_full PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo
title_fullStr PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo
title_full_unstemmed PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo
title_short PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo
title_sort pf-3845, a fatty acid amide hydrolase inhibitor, directly suppresses osteoclastogenesis through erk and nf-κb pathways in vitro and alveolar bone loss in vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919013/
https://www.ncbi.nlm.nih.gov/pubmed/33671948
http://dx.doi.org/10.3390/ijms22041915
work_keys_str_mv AT ihnhyejung pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT kimyiseul pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT limsoomin pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT baejongsup pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT jungjaechang pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT kimyeohyang pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT parkjinwoo pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT wangzhao pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT kohjeongtae pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT baeyongchul pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT baekmoonchang pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo
AT parkeuikyun pf3845afattyacidamidehydrolaseinhibitordirectlysuppressesosteoclastogenesisthrougherkandnfkbpathwaysinvitroandalveolarbonelossinvivo